MEET OUR CEO

 

IRIS BINCOVICH

Iris holds a BA in Chemistry from the Israel Institute of Technology. she is an experienced manager in the healthcare arena, with a proven track record in developing global business strategies to penetrate new markets. With nearly 20 years of international marketing biz dev and sales experience, she has led and managed a successful international transactions in the OTC, cosmetics and dermatology sector.
Iris was formerly the VP Global Marketing & Sales for the OTC botanical specialist Kamedis, where she established their successful International penetration to the international market. She has led the marketing & sales strategy for a variety of dermatology, cosmetic and OTC companies (Promedico (Wellcome), Pollogen (Lumenis; NASDAQ: LMNS), Starlet Derma, Power Paper). Iris has worked with leading international cosmetic companies (Estee Lauder, L'Oreal, J&J, Channel, etc.).

ABOUT

Innocan Pharma™ was established in October 2017, following years of intensive research and analysis into medical cannabis activity in Israel. Innocan Pharma™ Team leverage the capabilities of leading Israeli pharmaceutical industry executives, including Ron Mayron, former CEO of Teva Israel, Yoram Druker Co-founder Pluristem, Brainstorm and Cell Source Ltd, Iris Bincovich developing global business strategies ( Kamedis, Efal), and Nir Avram VP R&D at Careline and was previously a member of the pharmaceutical innovation team at Perrigo. Innoca Pharma™ believes that by merging pharma, science, and the therapeutic benefits of Cannabinoids, it is possible to create a truly effective topical treatments product line.

 

RESEARCH AND DEVELOPMENT

Our Best-in-Class Research and Development team has vast expertise in developing CBD-integrated formulations for topical use

We have experience in developing sufficiently numbers of formulations, working with clients to tailor formulate, meticulously selecting suitable active ingredients, fragrances, and ensuring that the product meets and exceeds performance expectations.

Our R&D department develops products integrating the most advanced technology and a wide range of the highest quality materials, ingredients, textures and fragrances. We cooperate closely with leading research institutes and global ingredient suppliers to ensure that we are always up to date on the latest trends related to safe, effective, and sustainable ingredients that go into our finished products.

Our R&D team is globally acknowledged for it’s high output of new and innovative products for brand owners and retailers on 5 continents. We identify market trends, customer needs and apply our extensive experience to develop new formulations and assist in packaging recommendation allowing unique consumer benefits.

Innocan Pharma has developed several lines of unique and innovative topical Cannabis formulations.  This platform provides the versatility to develop new topical products (both cosmetics & pharmaceutics) for the possible treatment of dermatological and other skin & hair conditions.

MEET OUR CTO

 

NIR AVRAM

Nir Avram is a senior consultant in the areas of pharmaceuticals and cosmetics with over 30 years of experience.

Nir consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations and synthesis of novel materials, to start-ups as well as established companies.

Nir is vice president of research & development at Emilia Cosmetics Israel and Emilia Resources in the US. Prior to this he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perigo. Previously he served as chief chemist at Zohar Dalia. He holds several patents.

Nir received an M.Sc. (Cum Laude) in organic chemistry from the Technion – Israel Institute of Technology, Haifa